Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

BACKGROUND: Patients with type 2 diabetes (T2D) and coronary artery disease (CAD) have increased risk of cardiac dysfunction. The diabetic heart is characterized by increased fatty acid oxidation and reduced glucose uptake resulting in reduced cardiac efficiency. Glucagon-like peptide-1 (GLP-1) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumarathurai, Preman, Anholm, Christian, Nielsen, Olav W., Kristiansen, Ole P., Mølvig, Jens, Madsbad, Sten, Haugaard, Steen B., Sajadieh, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960858/
https://www.ncbi.nlm.nih.gov/pubmed/27455835
http://dx.doi.org/10.1186/s12933-016-0425-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960858/
https://www.ncbi.nlm.nih.gov/pubmed/27455835
http://dx.doi.org/10.1186/s12933-016-0425-2

Ejemplares similares